BSE Live
Oct 01, 16:01Prev. Close
1952.70
Open Price
1942.25
Bid Price (Qty.)
1958.65 (1)
Offer Price (Qty.)
1970.00 (10)
NSE Live
Oct 01, 15:50Prev. Close
1952.70
Open Price
1952.70
Bid Price (Qty.)
1959.20 (1)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Glenmark Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,096.08 | 1,300.63 | 1,119.33 | 1,491.43 | 1,043.98 | |
| Net CashFlow From Operating Activities | 1,392.41 | 1,324.17 | 1,648.05 | 657.43 | 344.85 | |
| Net Cash Used In Investing Activities | -783.52 | -698.99 | -1,013.34 | -712.35 | -880.17 | |
| Net Cash Used From Financing Activities | -444.66 | -738.74 | -468.50 | 543.15 | 698.60 | |
| Foreign Exchange Gains / Losses | 9.76 | -183.52 | 10.78 | -289.00 | -69.89 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 174.00 | -297.08 | 176.99 | 199.24 | 93.39 | |
| Cash And Cash Equivalents Begin of Year | 936.28 | 1,233.36 | 1,056.36 | 857.12 | 763.74 | |
| Cash And Cash Equivalents End Of Year | 1,110.28 | 936.28 | 1,233.36 | 1,056.36 | 857.12 |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015